Blood cancer journal 2022 Apr 07
Core-binding factor acute myeloid leukemia: long-term outcome of 70 patients uniformly treated with "7+3".
Related Questions
Is there any data on combining the two?
New answer by at University of Chicago (June 22, 2025)
First, in terms of risk stratification, core binding factor (CBF) AML [whether inv16 or t(8;21)] is considered to be favorable risk by ELN22 even if a FLT3 mutation is present...